INTERPLAY Study
Summary
Hand and arm intensive therapy is important for improving lifelong outcomes for infants and toddlers with cerebral palsy (CP). This play-based therapy is delivered by caregivers who are coached by therapists. However, access to this therapy is very limited for Canadian children with CP younger than two years old. This project aims to first identify reasons that support or stop the delivery of intensive therapy from the viewpoints of caregivers, therapists, and healthcare administrators. Findings will inform the design of implementation strategies, with the goal of increasing intensive therapy delivered to infants and toddlers across Canada.
Eligibility
Eligible ages: 18 to 80
Accepts healthy participants: Yes
Inclusion criteria:
1) Parents or Caregivers of a child with Cerebral Palsy with a stronger/preferred hand.
2) Occupational Therapists who provide interventions to children with Cerebral Palsy.
3) Healthcare administrators, Clinical Practice Leads, Team Leads, or people responsible for managing pediatric occupational therapy programs.
Participate
Fill out the following form if you want to participate in this research
UCalgary Notice of Collection
The University of Calgary (UCalgary) respects your privacy and is
committed to ensuring the privacy of all students, staff, and community members. Your personal information is being
collected under the authority of section 4(c) of the Protection of Privacy Act (POPA). It will be collected, used
and disclosed for the purposes outlined in UCalgary’s
Notice of
Collection, Use and Disclosure of Personal Information and managed in accordance with UCalgary’s
Privacy
Management Program.
Your personal information may be input into automated systems to generate content or make decisions,
recommendations, or predictions. If you have questions regarding this notice or UCalgary’s collection,
use, or disclosure of your personal information, please contact
accessandprivacy@ucalgary.ca.
Additional information
Contact information
Contact the INTERPLAY Study Team
Principal investigator:
Christopher Kirton
Clinical trial:
No
REB-ID:
REB22-1692